What is MacroGenics?
MacroGenics is dedicated to the discovery and development of innovative monoclonal antibody-based therapeutics, primarily targeting cancer. Leveraging its advanced technology platforms and protein engineering capabilities, the company has successfully generated a portfolio of product candidates. These efforts have also led to strategic collaborations with prominent global pharmaceutical and biotechnology firms, positioning MacroGenics as a key player in the oncology therapeutic space. The company's focus on novel antibody engineering aims to create differentiated treatments for challenging diseases.
How much funding has MacroGenics raised?
MacroGenics has raised a total of $559M across 10 funding rounds:
Series D
$25M
Grant
$9.8M
Stock Offering
$83.8M
Stock Offering
$76.7M
Stock Offering
$141M
Stock Offering
$23.6M
Stock Offering
$110M
Series D (2008): $25M featuring InterWest Partners, Alta Partners, Red Abbey Venture Partners, Innovis Investments, Alexandria Venture Investments, Mitsubishi UFJ, Ventures West, OrbiMed, Nextech Venture, Eli Lilly and Company, RiverVest, CIDC, Arcus Ventures, and TPG Ventures
Grant (2010): $9.8M backed by National Institutes of Health
Stock Issuance/Offering (2013): $83.8M with participation from Undisclosed
Stock Issuance/Offering (2014): $76.7M led by Undisclosed
Stock Issuance/Offering (2015): $141M supported by Undisclosed
Stock Issuance/Offering (2017): $23.7M featuring Undisclosed
Stock Issuance/Offering (2018): $110M backed by Undisclosed
Key Investors in MacroGenics
MPM Capital
MPM Capital is a venture capital firm that manages early-stage venture funds, private/public impact funds, and a public equities fund, focusing on converting scientific breakthroughs into therapeutics.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
Alta Partners
Alta Partners is a venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
What's next for MacroGenics?
With the recent strategic investment and its substantial overall funding, MacroGenics is poised for accelerated development and potential commercialization of its therapeutic candidates. The company's trajectory suggests a focus on advancing its lead programs through clinical trials and expanding its research and development efforts. Future strategic moves may include further partnerships, licensing agreements, or additional financing rounds to support late-stage development and market entry, solidifying its position in the biopharmaceutical industry.
See full MacroGenics company page
